stockportfolio.pro
Stocks / NNNN vs OMER
NNNN vs OMER
Anbio Biotechnology and Omeros Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Anbio Biotechnology (NNNN) | Omeros Corporation (OMER) | |
|---|---|---|
| Market cap | $0.7B | $0.7B |
| Revenue (latest FY) | $8.65M | $0 |
| Net income (latest FY) | $6.40M | $-3.35M |
| Revenue growth (5y CAGR) | -28.4% | — |
| Net margin | 74.1% | — |
| Return on equity | 21.2% | 2.8% |
| P/E ratio | 107.4 | 9.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 4 | 2 |
| Positive free cash flow | — | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NNNN — free Open OMER — freeFrequently asked questions
Which is bigger, NNNN or OMER?
Omeros Corporation is larger by market capitalization — $0.7B versus $0.7B.
Which grows faster, NNNN or OMER?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.